Dolutegravir Plus Lamivudine Dual Therapy in Treatment Naïve HIV-1 Patients



Status:Completed
Conditions:HIV / AIDS
Therapuetic Areas:Immunology / Infectious Diseases
Healthy:No
Age Range:18 - Any
Updated:5/11/2018
Start Date:December 8, 2015
End Date:September 26, 2017

Use our guide to learn which trials are right for you!

A Study to Evaluate Dolutegravir Plus Lamivudine Dual Therapy for the Treatment of Naïve HIV-1-infected Participants

This study was done to see if the combination of two anti-HIV medicines, dolutegravir (DTG,
Tivicay) and lamivudine (3TC, Epivir) taken once a day, provide a safe, effective, and
well-tolerated treatment for HIV. DTG is a type of HIV medicine called an integrase
inhibitor; 3TC is a type of HIV medicine called a reverse transcriptase inhibitor. DTG works
by blocking integrase and 3TC works by blocking reverse transcriptase, two HIV proteins
(enzymes). This prevents HIV from multiplying and lowers the viral load (amount of HIV in the
blood). Both DTG and 3TC are currently part of Food and Drug Administration (FDA) recommended
regimens along with a third active drug. Since some HIV medicines have side effects and are
costly, there is interest in whether HIV can be successfully controlled with fewer than three
HIV drugs.

This study was a phase II, single-arm, open-label pilot study designed to estimate the
efficacy of dolutegravir (DTG) plus lamivudine (3TC) as initial combination ART
(antiretroviral therapy) in HIV-1 infected treatment naive participants. The target
enrollment was 120 participants with a cap of N=90 participants with screening HIV-1 RNA <=
100,000 copies/mL. The study aimed to enroll >= 20% women. The expected follow-up for each
participant was 52 weeks.

Visits occurred at screening, entry, and weeks 2, 4, 8, 12, 16, 20, 24, 32, 40, 48, and 52
from study entry. All signs/symptoms within 30 days prior to entry were recorded.
Subsequently, grade 2 or higher rash and all other grade 3 or higher signs and symptoms were
recorded. All participants underwent routine monitoring including plasma HIV-1 RNA levels,
CD4+ cell count, hematology, chemistry, urinalysis, and pregnancy testing (for women of
reproductive potential).

Population-based protease (PR), reverse transcriptase (RT) and integrase genotyping were done
at the time of confirmed virologic failure. Plasma samples were stored for potential future
studies to assess the impact of adherence, drug-resistant minority viral variants, and DTG
exposure on virologic and CD4+ cell count responses to DTG plus 3TC. All participants also
underwent UGT1A1 genotyping.

NOTE: Further information on the eligibility criteria can be found in the study protocol.

Inclusion Criteria:

- HIV-1 infection.

- Plasma HIV-1 RNA ≥1000 copies/mL and <500,000 copies/mL obtained within 90 days prior
to study entry.

- No evidence of any RT, any integrase, or major protease resistance mutation (according
to the 2014 IAS-USA drug resistance mutations list, available at
https://www.iasusa.org/sites/default/files/tam/22-3-642.pdf) based on pre-ARV
(antiretroviral) treatment genotype performed any time prior to study entry.

- ARV treatment drug-naive (defined as no previous ARV treatment at any time prior to
study entry, with the exception of successful post-exposure prophylaxis (PEP) or
pre-exposure prophylaxis (PrEP).

- The following laboratory values obtained within 45 days prior to study entry:

- ANC (absolute neutrophil count) ≥750/mm^3

- Hemoglobin ≥10.0 g/dL

- Platelets ≥ 50,000/mm^3

- Calculated creatinine clearance (CrCl) ≥50 mL/min, as estimated by the
Cockcroft-Gault equation

- AST (aspartate aminotransferase) <5 x ULN (upper limit of normal)

- ALT (alanine aminotransferase) <5x ULN

- Total bilirubin <1.5 x ULN

- Hepatitis B surface antigen negative within 45 days prior to study entry.

- For women with reproductive potential, negative serum or urine pregnancy test at
screening and within 48 hours prior to study entry.

- If participating in sexual activity that could lead to pregnancy, female participants
with reproductive potential must have agreed to use one form of contraceptive as
listed in the protocol while receiving protocol-specified medications and for 30 days
after stopping the medications.

- Ability and willingness of participant or legal representative to provide informed
consent.

Exclusion Criteria:

- Serious illness requiring systemic treatment and/or hospitalization.

- Treatment within 30 days prior to study entry with immune modulators such as systemic
steroids, interleukins, interferons, granulocyte colony-stimulating factor (G-CSF),
erythropoietin, or any investigational therapy.

- Pregnancy or breastfeeding.

- Receipt of systemic cytotoxic chemotherapy or dofetilide.

- Known allergy/sensitivity to any of the study drugs or their formulations.

- Active drug or alcohol use or dependence that may interfere with adherence to study
requirements, in the opinion of the site investigator.

- Active hepatitis C virus (HCV) treatment or anticipated need for treatment within
study period.

- Unstable liver disease (as defined by the presence of ascites, encephalopathy,
coagulopathy, hypoalbuminemia, esophageal or gastric varices, or persistent jaundice),
known biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic
gallstones).

- Severe hepatic impairment (Class C) as determined by Child-Pugh classification.
We found this trial at
26
sites
Nashville, Tennessee 37204
Principal Investigator: David Haas, MD
Phone: 615-936-8516
?
mi
from
Nashville, TN
Click here to add this to my saved trials
Atlanta, Georgia 30308
Principal Investigator: Carlos del Rio, MD
Phone: 404-616-6313
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
Aurora, Colorado 80045
Principal Investigator: Thomas B Campbell, MD
Phone: 303-724-0712
?
mi
from
Aurora, CO
Click here to add this to my saved trials
Boston, Massachusetts 02114
Principal Investigator: Rajesh T. Gandhi, MD
Phone: 1-617-724-0072
?
mi
from
Boston, MA
Click here to add this to my saved trials
Boston, Massachusetts 02115
Principal Investigator: Paul E. Sax, MD
Phone: 617-732-5635
?
mi
from
Boston, MA
Click here to add this to my saved trials
3201 Orange Chapel Clover Garden Road
Chapel Hill, North Carolina 27516
Principal Investigator: David A. Wohl, MD
Phone: 919-966-6712
?
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Chicago, Illinois 60611
Principal Investigator: Babafemi Taiwo, MBBS, MD
Phone: 312-695-5012
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Chicago, Illinois 60612
Principal Investigator: Beverly E Sha, MD
Phone: 312-942-4810
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Cincinnati, Ohio 45267
Principal Investigator: Carl Fichtenbaum, MD
Phone: 513-584-6383
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Columbus, Ohio 43210
Principal Investigator: Susan Koletar, MD
Phone: 614-293-5856
?
mi
from
Columbus, OH
Click here to add this to my saved trials
?
mi
from
Dallas, TX
Click here to add this to my saved trials
Greensboro, North Carolina 27401
Principal Investigator: Cornelius Van Dam, MD
Phone: 336-832-7888
?
mi
from
Greensboro, NC
Click here to add this to my saved trials
Houston, Texas 77030
Principal Investigator: Roberto C. Arduino, MD
Phone: 713-500-6718
?
mi
from
Houston, TX
Click here to add this to my saved trials
Los Angeles, California 90033
Principal Investigator: Fred Sattler, MD
Phone: 323-343-8283
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Los Angeles, California 90095
Principal Investigator: Raphael Landovitz, MD
Phone: 310-557-3798
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Miami, Florida 33139
Principal Investigator: Margaret A. Fischl, MD
Phone: 305-243-3838
?
mi
from
Miami, FL
Click here to add this to my saved trials
New York, New York 10011
Principal Investigator: Timothy Wilkin, MD, MPH
Phone: 212-746-7198
?
mi
from
New York, NY
Click here to add this to my saved trials
New York, New York 10011
Principal Investigator: Marshall J. Glesby, MD
Phone: 212-746-4177
?
mi
from
New York, NY
Click here to add this to my saved trials
New York, New York 10032
Principal Investigator: Magdalena Sobieszczyk, MD, MPH
Phone: 212-305-3178
?
mi
from
New York, NY
Click here to add this to my saved trials
Philadelphia, Pennsylvania 19104
Principal Investigator: Pablo Tebas, MD
Phone: 215-349-8091
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Providence, Rhode Island 02906
Principal Investigator: Karen T. Tashima, MD
Phone: 401-793-4971
?
mi
from
Providence, RI
Click here to add this to my saved trials
Rochester, New York 14642
Principal Investigator: Amneris Luque, MD
Phone: 585-276-5903
?
mi
from
Rochester, NY
Click here to add this to my saved trials
Saint Louis, Missouri 63110
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
San Diego, California 92103
Principal Investigator: Constance Benson, MD
Phone: 619-543-8080
?
mi
from
San Diego, CA
Click here to add this to my saved trials
San Juan, 00935
Principal Investigator: Jorge L Santana-Bagur, MD
Phone: 787-767-9192
?
mi
from
San Juan,
Click here to add this to my saved trials
Torrance, California 90502
?
mi
from
Torrance, CA
Click here to add this to my saved trials